drugset / Trial / NCT06578949

Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT06578949

Phase 3 Completed 18 enrolled Alexion Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the efficacy of ravulizumab in adult participants with PNH.

Timeline

Start
2024-10-10
Primary completion
2025-05-15
Completion
2025-12-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Ravulizumab Monoclonal antibody Intravenous